Lipid variability in patients with diabetes mellitus

Abstract

Diabetic dyslipidemia is characterized by hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), elevated low-density lipoprotein cholesterol (LDL-C), and the predominance of small dense LDL particles caused by insulin resistance in patients with type 2 diabetes mellitus (DM) or insulin deficiency in patients with type 1 DM. Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease in individuals with DM, and lowering lipid levels can reduce the associated morbidity and mortality. The current guidelines for dyslipidemia management recommend an LDL-C goal lower than 55 to 100 mg/dL, depending on the underlying risk factors. However, greater visit-to-visit variability in cholesterol levels might be an independent predictor of major adverse cardiovascular events, high incidence of atrial fibrillation, poor renal outcomes, and cognitive dysfunction in patients with DM. This review focuses on the clinical implications of lipid variability in patients with DM.

Modulatory effect of aqueous leaf extract of Terminalia catappa on dyslipidemia in alloxan induced diabetic rats

“…In the diabetic untreated group, the level of LDL was significantly increased. The result is in line with many research reports [68,69] but does not agree with a reports that LDL-c is normal in diabetic condition [49] However, the administration of extract in diabetic+extract group reduced the LDL-c to level not different from control. The observed reduction is consistent with [70,71,72].…”